The fund is a new $125M fund jointly founded by a New York-based firm and a Korea-based firm in 2021. The New York based firm is a global investment banking and strategic advisory firm specialized in life sciences, with decades of experience in supporting multiple leading life science companies. The Korea-based firm is a subsidiary of a leading Korean venture capital firm with over 30 years of investment experience. The firm seeks to invest between $2-10M (over the company’s lifespan) in therapeutics and medical device companies, with its sweet spot being Series A financings. The firm is actively sourcing deals globally with a focus on USA.
The fund seeks to invest 80% in therapeutics and 20% in medical devices. Indication-wise, the firm is most interested in oncology, CNS, cardiovascular, and rare diseases. The firm expects companies to already be conducting IND enabling studies or are currently running clinical trials. The firm will consider all types of modalities. The firm also has a broad interest in all types of medical devices, from traditional devices to cell therapy equipment, and will consider devices of all regulatory pathways including 510k and PMA.
The fund has no specific company or management team requirements. The firm is open to leading, co-leading, and co-investing, and will seek board representation when they act as the lead investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply